Sensorion SA announced that Federico Mingozzi, Ph.D., is joining the board of directors as a Non-Executive Director by way of co-optation, effective as of January 25, 2024. Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer. Federico brings over 25 years of experience in gene therapy, immunology, as well as biochemistry and molecular biology in academia and industry.

He is well known for his significant contributions to the development of gene therapies various diseases. Furthermore, he has played a key role in advancing understanding of the interactions between gene therapy vectors and the host immune system, as well as in the formulation of strategies to overcome immune responses to anti-AAV vectors. Prior to joining Spark Therapeutics, Federico Mingozzi was Head of the Immunology and Liver Gene Transfer Unit at Genethon, Research Director at INSERM, the French National Institute of Health and Medical Research, and Director at the Children?s Hospital of Philadelphia.

Federico holds a bachelor?s degree in biology and his Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy, and his M.B.A. from Drexel University.